Underuse of anthracyclines in women with HER-2+ advanced breast cancer.

Item

http://www.wikidata.org/entity/Q35584166

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Underuse of anthracyclines in women with HER-2+ advanced breast cancer.

@ast

Underuse of anthracyclines in women with HER-2+ advanced breast cancer.

@en

type

Item

label

Underuse of anthracyclines in women with HER-2+ advanced breast cancer.

@ast

Underuse of anthracyclines in women with HER-2+ advanced breast cancer.

@en

prefLabel

Underuse of anthracyclines in women with HER-2+ advanced breast cancer.

@ast

Underuse of anthracyclines in women with HER-2+ advanced breast cancer.

@en

P1476

Underuse of anthracyclines in women with HER-2+ advanced breast cancer.

@en

P2093

Elena Verri

http://www.w3.org/2001/XMLSchema#string

Filippo Montemurro

http://www.w3.org/2001/XMLSchema#string

Franco Nolè

http://www.w3.org/2001/XMLSchema#string

Maria Cossu Rocca

http://www.w3.org/2001/XMLSchema#string

Maria Elena Jacomuzzi

http://www.w3.org/2001/XMLSchema#string

Michela Donadio

http://www.w3.org/2001/XMLSchema#string

Rossella Martinello

http://www.w3.org/2001/XMLSchema#string

Stefania Redana

http://www.w3.org/2001/XMLSchema#string

Valentina Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

Multiple essential functions of neuregulin in development

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.

Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

P304

665-672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2010-0016

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44798712

http://www.w3.org/2001/XMLSchema#string

P698

20576644

http://www.w3.org/2001/XMLSchema#string

P932

3228005

http://www.w3.org/2001/XMLSchema#string